A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/dfbfe247-42b4-450d-b7c4-90ebe00d8ee7
REGENXBIO Inc. is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO’s NAV® Technology platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO’s most advanced internally developed candidates include programs for the treatment of two severe and rare genetic diseases, homozygous familial hypercholesterolemia and Mucopolysaccharidosis Type I.
“REGENXBIO Inc. offers a gene therapy technology platform that seeks to transform the lives of patients suffering from severe diseases with significant unmet medical need,” said Nelson Griggs, Executive Vice President, Listing Services at Nasdaq. “We are proud to welcome REGENXBIO to our family of pioneering companies, and we look forward to supporting its future growth and success.”
By listing with Nasdaq, REGENXBIO Inc. joins many of the world’s largest and most revolutionary companies. Nasdaq is the exchange of choice to 78 percent of health care companies listed on U.S. markets.
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of approximately $9.6 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.
CONTACT: Media Relations Contacts: Will Briganti (646) 441-5012 email@example.com Angela Tu (646) 225-0316 firstname.lastname@example.org